Nalaganje...
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing t...
Shranjeno v:
| izdano v: | Diabetes Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6965597/ https://ncbi.nlm.nih.gov/pubmed/31813092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00728-6 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|